Search
Showing results for "Childhood interstitial lung disease "
Dr Daniel Laucirica, a research officer with the Wal-yan Respiratory Research Centre, will undertake new research into potential treatment strategies to prevent lung damage in people with cystic fibrosis (CF), under the mentorship of Associate Professor Anthony Kicic - made possible by a Vertex Cyst
WA researchers will use a $1.97 million Medical Research Future Fund grant to develop a strategy for better follow-up of First Nations children after they’ve been hospitalised for respiratory infections, in a bid to halt the slide into more severe lung disease.
These findings suggest the utility of specific FOT outcomes is dependent on the respiratory disease being assessed
Structural and functional defects within the lungs of children with cystic fibrosis (CF) are detectable soon after birth and progress throughout preschool years often without overt clinical signs or symptoms. By school age, most children have structural changes such as bronchiectasis or gas trapping/hypoperfusion and lung function abnormalities that persist into later life. Despite improved survival, gains in forced expiratory volume in one second (FEV1) achieved across successive birth cohorts during childhood have plateaued, and rates of FEV1 decline in adolescence and adulthood have not slowed. This suggests that interventions aimed at preventing lung disease should be targeted to mild disease and commence in early life.
The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis Lung inflammation and infection are common
Identifying pediatric lung disease: A comparison of forced oscillation technique outcomes Abstract Rationale Increasing evidence suggests the forced
Improvements in neonatal critical care have resulted in more people than ever reaching adulthood after being born prematurely. At the same time, it is becoming clearer that preterm birth can increase the risk of respiratory disease throughout a person’s lifetime. Awareness that a patient was born preterm can enable early specialist assessment and intervention when there is any concern about lung health.
Shannon Elizabeth Simpson Smith BMedSci (hons), PhD PhD, MSc, BSc Head, Strong Beginnings Research, Co-head Foundations of Lung Disease Program
Biomarkers in cystic fibrosis are used for the measurement of cystic fibrosis transmembrane regulator function in order to diagnose cystic fibrosis,...
Our data associates IL-1α with early structural lung damage in CF and suggests this pathway as a novel anti-inflammatory target